LWM
AVDL

Liberty Wealth Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Liberty Wealth Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-85
Closed – – 903
2019
Q3 		$0 Hold
85
– – ﹤0.01% 865
2019
Q2 		$0 Hold
85
– – ﹤0.01% 899
2019
Q1 		$0 Hold
85
– – ﹤0.01% 731
2018
Q4 		$0 Buy
+85
New +$289 ﹤0.01% 753

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Liberty Wealth Management's AVDL Position: Q4 2019 in Review

Liberty Wealth Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2019, closing a stake of 85 shares.

Liberty Wealth Management first reported a position in AVDL in Q4 2018 and held it in 4 quarters. The position peaked at $0 in Q3 2019. 42 funds tracked by Wall St. Rank hold AVDL as of Q4 2019.

  • Liberty Wealth Management reported no remaining Avadel Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Liberty Wealth Management sold 85 Avadel Pharmaceuticals shares in Q4 2019.
  • Liberty Wealth Management first reported a position in Avadel Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Liberty Wealth Management's Avadel Pharmaceuticals position peaked at $0 in Q3 2019.
  • 42 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2019.

Based on Liberty Wealth Management's 13F filing for Q4 2019, filed 5 Feb 2020.